Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

BACKGROUND: Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FGF recept...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Lee, Eudocia Q., Muzikansky, Alona, Duda, Dan G., Gaffey, Sarah, Dietrich, Jorg, Nayak, Lakshmi, Chukwueke, Ugonma N., Beroukhim, Rameen, Doherty, Lisa, Laub, Caroline Kane, LaFrankie, Debra, Fontana, Brittney, Stefanik, Jennifer, Ruland, Sandra, Caruso, Victoria, Bruno, Jennifer, Ligon, Keith, Reardon, David A., Wen, Patrick Y.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://ncbi.nlm.nih.gov/pubmed/31444999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2505
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia